GlaxoSmithKline Australia Pty Ltd v Pharmacor Pty Ltd [2014] FCA 1202

GlaxoSmithKline Australia Pty Ltd v Pharmacor Pty Ltd [2014] FCA 1202

GSK established a reasonable belief that promotion of Pharmacor Products to pharmacists and consumers as 'bioequivalent' or 'brand equivalent' may constitute misleading or deceptive conduct under ss 18 and 29 of the ACL due to omission or silence about material differences, justifying an order for preliminary discovery under r 7.23. No reasonable belief for patent infringement claim was found.

Jurisdiction
Australia
Judgment Date
12 November 2014
Procedural Posture
Application for Preliminary Discovery / Judgment on Application
Outcome
Order for preliminary discovery made in favour of the applicant (GSK) on ACL claims regarding misleading or deceptive conduct; patent infringement claim not established.
Legal Topics
['preliminary Discovery' 'misleading or Deceptive Conduct' 'false or Misleading Representations' 'patent Infringement' 'bioequivalence of Pharmaceutical Products']
['practice and Procedure' 'consumer Law' 'intellectual Property Law'] ['preliminary Discovery' 'misleading or Deceptive Conduct' 'false or Misleading Representations' 'patent Infringement' 'bioequivalence of Pharmaceutical Products']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Procedural Posture

Application for Preliminary Discovery / Judgment on Application

Legal Issues

  1. 1 ['Whether GSK has a reasonable belief for relief against Pharmacor under ss 18 and 29 of the ACL concerning promotion of Pharmacor Products' 'Whether GSK is entitled to preliminary discovery under r 7.23 of the Federal Court Rules 2011 (Cth)' 'Whether GSK has a claim for patent infringement']

Ratio Decidendi

GSK established a reasonable belief that promotion of Pharmacor Products to pharmacists and consumers as 'bioequivalent' or 'brand equivalent' may constitute misleading or deceptive conduct under ss 18 and 29 of the ACL due to omission or silence about material differences, justifying an order for preliminary discovery under r 7.23. No reasonable belief for patent infringement claim was found.

Court Disposition

Order for preliminary discovery made in favour of the applicant (GSK) on ACL claims regarding misleading or deceptive conduct; patent infringement claim not established.

Orders

  • ['The parties are to confer forthwith as to the precise form of the preliminary discovery orders to be made to accord with the reasons published.' 'The application be stood over until 9.30 am on 13 November 2014.' 'Costs reserved.']